Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disea...(king statements include statements about...),Health

Date:8/19/2008

king statements include statements about the Karolinska Institutet's and the SMI's plans for a prime-boost HIV vaccine clinical trial, the potential effect of the company's Vaxfectin(R) adjuvant and Biojector(R) 2000 needle-free injection system on vaccine performance, and the design and potential benefits of HIV DNA vaccines generally. Risks and uncertainties include whether Vical, the Karolinska Institutet the SMI or others will continue development of the HIV vaccine; whether the SMI will sponsor and the Karolinska Institutet will complete preclinical testing and conduct a Phase 1 trial using a Vaxfectin(R)-formulated DNA prime-MVA boost vaccination regimen; whether such trial, if conducted, will use the Biojector(R) 2000 needle-free injection system to deliver the DNA priming vaccine; whether Vaxfectin(R) will optimize the DNA vaccine priming of immune responses against the specific HIV vaccine targets and increase the performance of, or eliminate the need for, the MVA vaccine boost; whether Vaxfectin(R)-formulated DNA priming vaccines will increase the breadth and magnitude of immune responses to the prime-boost regimen; whether the prime-boost vaccine regimen will be effective in protecting humans against HIV infection or disease; whether the HIV vaccine will achieve the safety and immunogenicity endpoints in the Phase 1 trial; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: ht
'/>"/>

SOURCE Vical Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
2. Nventa Develops Proprietary Vaccine Adjuvant
3. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
4. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
5. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
6. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. U.S. Preventive Medicine: Employers Can Help Workers Avoid Heart Attacks
9. Inhaled Steriods Used as Preventive Treatment Post 9/11
10. U.S. Preventive Medicine Acquires Specialty Disease Management
11. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US